2004
DOI: 10.1089/cbr.2004.19.658
|View full text |Cite
|
Sign up to set email alerts
|

Phase I/II Trial of Melanoma Patient–Specific Vaccine of Proliferating Autologous Tumor Cells, Dendritic Cells, and GM-CSF: Planned Interim Analysis

Abstract: Based on tolerability, rate of tumor DTH conversion, and encouraging survival, the trial will continue accrual to at least 19 patients with measurable disease and 40 patients who lack measurable disease at the time of treatment.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
12
0

Year Published

2006
2006
2017
2017

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 33 publications
(12 citation statements)
references
References 14 publications
0
12
0
Order By: Relevance
“…Included (group A, helper antigen and/or adjuvant + ): Chang et al. (2002, 2009), Dillman et al. (2004, 2009), Escobar et al.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Included (group A, helper antigen and/or adjuvant + ): Chang et al. (2002, 2009), Dillman et al. (2004, 2009), Escobar et al.…”
Section: Resultsmentioning
confidence: 99%
“…Effective antigen presentation by DCs followed by strong induction of tumor antigen‐specific T cells and alteration of the tumor microenvironment are required for improving the clinical effect. To date, 54 DC vaccination clinical trials have been performed (Akiyama et al., 2005; Banchereau et al., 2001, 2005; Barbuto et al., 2004; Bedrosian et al., 2003; Bercovici et al., 2008; Butterfield et al., 2003; Chang et al., 2002, 2009; Davis et al., 2006; Dillman et al., 2004, 2009; Di Nicola et al., 2004; Escobar et al., 2005; Escudier et al., 2005; von Euw et al., 2008; Gilliet et al., 2003; Griffioen et al., 2004; Grover et al., 2006; Haenssle et al., 2004; Hersey et al., 2004, 2008; Jonuleit et al., 2001; Krause et al., 2002; Kyte et al., 2006; Lau et al., 2001; Lesimple et al., 2006; Linette et al., 2005; Mackensen et al., 2000; Nagayama et al., 2003; Nakai et al., 2006, 2008; Nestle et al., 1998; O’Rourke et al., 2003, 2007; Palucka et al., 2003, 2006; Panelli et al., 2000; Redman et al., 2008; Ribas et al., 2004, 2009; Ridolfi et al., 2006; Salcedo et al., 2006; Schadendorf et al., 2006; Schuler‐Thurner et al., 2000, 2002; Slingluff et al., 2003; Smithers et al., 2003; Thurner et al., 1999; Trakatelli et al., 2006; Trefzer et al., 2004; Tuettenberg et al., 2006; Vilella et al., 2004; de Vries et al., 2003; Wei et al., 2006). The first summary of the results of DC vaccination from 626 patients in 38 trials (Engell‐Noerregaard et al., 2009) showed a significant effect in patients with stable disease (SD) with regard to clinical responses to peptide antigens, adjuvant, and induction of antigen‐specific T cells.…”
Section: Introductionmentioning
confidence: 99%
“…This is indeed one of the qualities that make GM-CSF such a good candidate for cancer vaccination, including non-DC therapies (90). The type I IFN bias is further supported by studies where the outcome of GM-CSF administration is similar to that of patients receiving IFN-gamma as an adjuvant, by increased responses to tumor-derived antigens (80,91,92). Furthermore, T cells proliferate respond when stimulated with autologous tumor cells that secrete cytokines like IL-2, IFN-gamma, GMCSF and TNF-alpha (93).…”
Section: Methods To Improve DC Potencymentioning
confidence: 95%
“…Animal studies with IFN-gamma did demonstrate a considerable boost in antigen-specific CTL responses when combining it with LPS or CpG. Type I IFNs are not as well supported as type II since it produces a significant amount of toxicity (92,99).…”
Section: Methods To Improve DC Potencymentioning
confidence: 99%
“…Indeed, a randomized phase II comparison of autologous tumor antigen-pulsed dendritic cells versus autologous whole cell vaccination showed a survival advantage in the dendritic cell arm (HR 0.27, 95% CI 0.098–0.729). 16 Additional considerations of dendritic cell vaccines are considered below.…”
Section: Autologous Melanoma Vaccinesmentioning
confidence: 99%